Curative Biosciences, Inc. (CBDX) financial statements (2020 and earlier)
Company profile
| Business Address |
5042 WILSHIRE BLVD. LOS ANGELES, CA 90036 |
| State of Incorp. | NV |
| Fiscal Year End | June 30 |
| SIC | 209 - Miscellaneous Food Preparations And Kindred (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 3/31/2018 TTM | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | 0 | |||||
| Cash and cash equivalents | 0 | 0 | 0 | |||||
| Prepaid expense | 0 | ✕ | ||||||
| Other undisclosed current assets | 0 | |||||||
| Total current assets: | 0 | 0 | 0 | |||||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | ||||
| Intangible assets, net (including goodwill) | (0) | 0 | ✕ | |||||
| Intangible assets, net (excluding goodwill) | (0) | 0 | ||||||
| Other undisclosed noncurrent assets | 0 | (0) | 0 | |||||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 0 | |||
| Other undisclosed assets | 0 | |||||||
| TOTAL ASSETS: | 0 | 0 | 0 | 0 | 0 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 0 | 0 | 0 | 0 | 0 | |||
| Accounts payable | 0 | 0 | 0 | 0 | 0 | |||
| Accrued liabilities | 0 | 0 | 0 | |||||
| Employee-related liabilities | 0 | 0 | 0 | 0 | ||||
| Taxes payable | 0 | 0 | 0 | 0 | ||||
| Debt | 0 | 0 | ||||||
| Estimated litigation liability | 0 | 0 | ||||||
| Due to related parties | 0 | |||||||
| Other undisclosed current liabilities | 0 | 0 | 0 | 0 | 1 | |||
| Total current liabilities: | 1 | 1 | 1 | 0 | 1 | |||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 1 | 1 | 1 | 0 | 1 | |||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | (1) | (1) | (1) | (0) | (1) | |||
| Common stock | 0 | 0 | 0 | 0 | ||||
| Additional paid in capital | 53 | 52 | 51 | 48 | 18 | |||
| Accumulated deficit | (53) | (53) | (51) | (18) | ||||
| Other undisclosed stockholders' equity attributable to parent | (30) | (18) | ||||||
| Total stockholders' equity: | (1) | (1) | (1) | (0) | (1) | |||
| TOTAL LIABILITIES AND EQUITY: | 0 | 0 | 0 | 0 | 0 | |||
Income statement (P&L) ($ in millions)
| 3/31/2018 TTM | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | |||||
| Revenue, net | 0 | ||||||
| Cost of revenue | (0) | ||||||
| Gross profit: | 0 | 0 | |||||
| Operating expenses | (0) | (2) | 3 | (30) | (1) | ||
| Other undisclosed operating loss | (0) | ||||||
| Operating income (loss): | (0) | (2) | 3 | (30) | (1) | ||
| Income (loss) before gain (loss) on sale of properties: | (0) | (2) | 3 | (30) | (1) | ||
| Other undisclosed net loss | (7) | ||||||
| Net loss: | (0) | (2) | (3) | (30) | (1) | ||
| Other undisclosed net loss attributable to parent | (6) | ||||||
| Net loss available to common stockholders, diluted: | (0) | (2) | (3) | (30) | (7) | ||
Comprehensive Income ($ in millions)
| 3/31/2018 TTM | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (0) | (2) | (3) | (30) | (1) | ||
| Comprehensive loss, net of tax, attributable to parent: | (0) | (2) | (3) | (30) | (1) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.